Regeneron Pharmaceuticals Inc  $820.00

Regeneron Pharmaceuticals, Inc. is a renowned biotechnology company based in Tarrytown, New York. It employs a highly skilled workforce of 10,368 full-time employees and is dedicated to the discovery, invention, development, manufacture, and commercialization of innovative medicines. The company has a broad portfolio of commercialized medicines and product candidates in development designed to help patients with various diseases such as eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Some of the company's successful marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, and Praluent (alirocumab) Injection, which have helped millions of patients worldwide. The company's other products such as REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion are also highly effective in treating various diseases. Regeneron Pharmaceuticals also provides Expresse service assurance and CloudCheck WiFi experience management solutions. As a publicly traded company, investors can track the performance of Regeneron Pharmaceuticals through various financial indicators such as share price, stock price, market cap, and price share. It is worth noting that Regeneron Pharmaceuticals has a strong reputation for producing high-quality medicines, and its stock price today and stocks share price today are widely watched by investors. The company's stock is also actively traded in the premarket and global stock exchanges, with its price in Malaysia being closely monitored by investors in the Asia-Pacific region.